Chimeric antigen receptor T cell therapy has reshaped expectations for treating hematological malignancies and is now reaching toward autoimmune ...

The new CAR T-cell generations aim to enhance efficacy in solid tumors, ... This approach minimizes cell fatigue, enhances antitumor activity, and enables lower dosing, ...

However, CAR-T cell therapy still faces many challenges owing to the heterogeneity of tumor cells, interference from TME, T cell exhaustion, as well as severe adverse events.

CD8⁺ T cells are the immune system's frontline warriors, charged with detecting and eliminating cancer cells. But in the hostile and chronic environment of tumors, these cells often falter.

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing cancer cells Minerva ...

PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer ...

According to the therapy's developer, this enables high CAR expression without tonic signaling that results in T-cell exhaustion, and it is designed to quickly release from the BCMA target.

I mmunotherapies such as immune checkpoint inhibitors and CAR T cell therapy, which boost the cancer-fighting properties of patients’ own immune cells, have revolutionized the treatment of ...